Field Medical Advisor Hematology Turkey

Field Medical Advisor

reporting to Medical Lead Hematology

70% Field based

This is an exciting opportunity for an experienced Medical Professional looking for a new challenge in an environment where your impact will be instantly visible. It is a chance to become an integral member of a small, highly motivated team tasked with delivering results and given the autonomy to define how they are achieved. As our Field Medical Advisor, you will have a deep understanding of the relevant therapy area and our clinical trial data. As the medical and scientific expert for Turkiye, you will be significantly contributing to the launch planning and execution with a cross-functional team. You will work closely with key external stakeholders and have a direct reporting line to the Medical Lead. Individuals inspired by the possibility to raise awareness, educate and shape the medical landscape in preparation for the launch of new first in class therapies will thrive in this role.

Responsibilities

• Works closely with the Medical Lead to establish a medical footprint for Menarini-Stemline in Turkiye.
• Establishes, develops and manages collaborative relationships with key medical experts and opinion leaders of Turkiye in relation to any current and future disease areas relevant for Menarini-Stemline
• Build relationships with key external stakeholders in relevant therapeutic areas and provide high-quality scientific expertise as a trusted partner and gather insights to guide the development of strategy and tactics
• Organises and leads expert meetings to gather insights and enrich strategic thinking
• Drives disease awareness in providing external medical disease education and setting up local scientific programs, such as symposia, regional advisory boards, or scientific meetings in accordance with the respective Menarini-Stemline disease plans
• Develop and deliver therapy area and product related educational content for HCP audiences
• Support cross functional colleagues and provide appropriate medical input into a wide variety of activities
• Work cross-functionally with colleagues across medical affairs, market access, commercial, etc. to establish ongoing collaborative internal relationships to prepare the launch of new substances in the field from a scientific and medical affairs perspective
• Provides medical support and medical information for unsolicited HCP requests related to any Menarini-Stemline in-line and pipe-line products in accordance with the relevant Menarini-Stemline processes and local regulations
• Is an active member of scientific and educational interactions with therapeutic specialists on diagnostic and clinically relevant aspects of any therapeutic areas in which Menarini-Stemline is active.
• Pro-actively supports internal medical knowledge development and provides internal training for sales and other functions on any relevant disease and product related aspects, in alignment with Medical Affairs Strategy
• Supports local aspects of investigator-initiated trials or other research projects
• Ensures that all activities required by pharmacovigilance and risk management are planned, set-up and pursued in accordance with respective local laws
• Ensures legal excellence and compliance in all medical activities as per Menarini-Stemline SOPs and local regulations

Skills/Knowledge

• Requires at least 2-3 years’ experience in the pharmaceutical industry in a similar role (Candidates with the exact therapeutic area (Hematology experience is strongly preferred)
• Graduates of Medical or Pharmacy Schools can apply only
• Previous experience of product launch is a plus
• The roll will require strong scientific acumen, preferably a background in hematologic and solid tumour malignancies (ideally within multiple myeloma or breast cancer)
• Knowledge of haematology /oncology segments and dynamics
• Proven basic science and/or clinical background to enable engagement of internal and external stakeholders in a scientifically meaningful exchange
• Experience in developing and delivering internal training on the relevant therapy area and clinical trial data to the customer facing teams
• Ability to work independently in a fast-paced environment, to anticipate and adapt to change
• Excellent written and oral communication skills and ability to engage in collaborative decision making
• Strong communication skills, open style & pro-active
• Entrepreneurial spirit and self-driven personality
• Mobile, willing to travel extensively in the region.
• Must have a valid driver’s licence and the ability to travel by car or public transportation as needed.
• While performing the functions of this position, the individual must be able to frequently sit, stand, walk and drive a vehicle for an extended period. Travel is required to customer sites, including overnight travel that will vary depending on territory. Minimum expected travel is 70%
• Fluent English is essential
• Passionate about making a meaningful difference for patients and caregivers
• Motivated, self-starter who engages quickly and operates very effectively

About the company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines and is launched in Germany.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and launched it in February to the US market with the EMA review process is ongoing.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.